Successful Treatment of a Patient With Severe Calcific Uremic Arteriolopathy (Calciphylaxis) by Etidronate Disodium

American Journal of Kidney Diseases

Volumn 48, Issue 1, 2006, Pages 151-154

  Shiraishi, Naoki ^a,b   Kitamura, Kenichiro ^a,b   Miyoshi, Taku ^a,b   Adachi, Masataka ^a,b   Kohda, Yukimasa ^a,b   Nonoguchi, Hiroshi ^a,b   Misumi, Shuuko ^a,b   Maekawa, Yoshihiro ^a,b   Murayama, Toshihiko ^a,b   Tomita, Masao ^a,b   Tomita, Kimio ^a,b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

Author keywords

bisphosphonate; Calcemic uremic arteriolopathy (CUA); calciphylaxis; etidronate; hemodialysis (HD); renal failure; sevelamer hydrochloride

Indexed keywords

ANTIBIOTIC AGENT; CALCIUM; ETIDRONIC ACID;

ADULT; ANTIBIOTIC THERAPY; ARTERY DISEASE; ARTICLE; CALCIFIC UREMIC ARTERIOLOPATHY; CALCIUM BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE SEVERITY; EPITHELIZATION; FEMALE; GENERAL CONDITION DETERIORATION; HEMODIALYSIS; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; MEDICAL EXAMINATION; SKIN BIOPSY; SKIN NECROSIS; SKIN ULCER; THERAPY EFFECT; TISSUE SECTION; TREATMENT OUTCOME; TREATMENT RESPONSE; WHOLE BODY AUTORADIOGRAPHY; WOUND CARE;

BONE DENSITY CONSERVATION AGENTS; CALCIPHYLAXIS; ETIDRONIC ACID; FEMALE; HUMANS; MIDDLE AGED; RENAL DIALYSIS; SKIN ULCER; TREATMENT OUTCOME;

EID: 33745219882     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.04.062     Document Type: Article

References (17)

1. Wilmer W.A., and Magro C.M. Calciphylaxis. Emerging concepts in prevention, diagnosis, and treatment. Semin Dial 15 (2002) 172-186
2. Don B.R., and Chin A.I. A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. Clin Nephrol 59 (2003) 463-470
3. Fine A., and Zacharias J. Calciphylaxis is usually non-ulcerating. Risk factors, outcome and therapy. Kidney Int 61 (2002) 2210-2217
4. Fleisch H. Development of bisphosphonates. Breast Cancer Res 4 (2002) 30-34
5. Kramsch D.M., Aspen A.J., and Rozler L.J. Atherosclerosis. Prevention by agents not affecting abnormal levels of blood lipids. Science 213 (1981) 1511-1512
6. Price P.A., Omid N., Than T.N., and Williamson M.K. The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 71 (2002) 356-363
7. Miller S., Vernon-Roberts E., and McClure J. Cutaneous calciphylactic reactions in the mouse and the rat and the effects of diphosphonates on the reaction in the rat. J Pathol 142 (1984) 7-13
8. Rosenblum I.Y., Black H.E., and Ferrell J.F. The effects of various diphosphonates on a rat model of cardiac calciphylaxis. Calcif Tissue Res 23 (1977) 151-159
9. Janigan D.T., Hirsch D.J., Klassen G.A., and MacDonald A.S. Calcified subcutaneous arterioles with infarcts of the subcutis and skin ("calciphylaxis") in chronic renal failure. Am J Kidney Dis 35 (2000) 588-597
10. Rodd C. Bisphosphonates in dialysis and transplantation patients. Efficacy and safety issues. Perit Dial Int 21 suppl 3 (2001) S256-S260
11. Nitta K., Akiba T., Suzuki K., et al. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44 (2004) 680-688
12. Hashiba H., Aizawa S., Tamura K., Shigematsu T., and Kogo H. Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. Ther Apher Dial 8 (2004) 241-247
13. Phanish M.K., Kallarackal G., Ravanan R., Lawson T.M., and Baboolal K. Tumoral calcinosis associated with pyrexia and systemic inflammatory response in a haemodialysis patient. Successful treatment using intravenous pamidronate. Nephrol Dial Transplant 15 (2000) 1691-1693
14. Monney P., Nguyen Q.V., Perroud H., and Descombes E. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant 19 (2004) 2130-2132
15. Fischer A.H., and Morris D.J. Pathogenesis of calciphylaxis. Study of three cases with literature review. Hum Pathol 26 (1995) 1055-1064
16. Pennanen N., Lapinjoki S., Urtti A., and Monkkonen J. Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res 12 (1995) 916-922
17. Monkkonen J., Pennanen N., Lapinjoki S., and Urtti A. Clodronate (dichloromethylene bisphosphonate) inhibits LPS-stimulated IL-6 and TNF production by RAW 264 cells. Life Sci 54 (1994) PL229-PL234